NMRA Neumora Therapeutics, Inc.

NASDAQ
$0.68

Neumora Therapeutics, Inc. (NMRA) is expected to report earnings on November 10, 2026, before the market open. The consensus earnings estimate is a loss of $0.19 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -59.9% since its last earnings release on August 14, 2026.

Neumora Therapeutics, Inc. Reported In-line with Estimates
Friday, August 14, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 10
Tuesday · 7:00 AM ET
Earnings Whisper
-
vs ($0.19)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.05

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Neumora Therapeutics, Inc.

Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. Its therapeutic pipeline currently consists of clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Neumora Therapeutics Inc. is based in WATERTOWN, Mass.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.